TrialJapanese journal of clinical oncology2026

Sacituzumab govitecan in Japanese participants with HR+/HER2- metastatic breast cancer: primary results from the phase II ASCENT-J02 study.

Akihiko Shimomura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.